NASDAQ$CMPS
COMPASS Pathways plc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter and provided an update on recent business progress.
Compass Pathways reported a net loss of $35.2 million, or $0.55 loss per share, for the three months ended March 31, 2024. The company's cash and cash equivalents were $262.9 million as of March 31, 2024.
- COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025
- Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)
- Michael Gold to join Compass as Head of R&D
- Compass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care
Headline financials
Revenue & EPS history
COMPASS · Revenue · Quarterly
$0
Forward guidance
Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million. The full-year 2024 net cash used in operating activities is expected to be in the range of $110 million to $130 million and assumes the 2023 R&D tax credit is received in 4Q 2024. The cash position at March 31, 2024, is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
-0.7%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.1%
Avg return
30 days after
32%
6 / 19 earnings
Positive
+25.1%
Q2 2022
Best reaction
-23.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -5.9% | +12.7% | +29.1% | |
| Q3 2025 | -0.5% | +4.7% | -12.3% | |
| Q1 2025 | +0.5% | +4.3% | +28.3% | |
| Q4 2024 | +5.9% | +4.1% | -20.5% | |
| Q3 2024 | -23.3% | -27.0% | -25.8% | |
| Q1 2024 | +0.0% | -4.9% | -18.7% | |
| Q4 2023 | -7.2% | -12.1% | -32.7% | |
| Q3 2023 | +10.9% | +4.7% | +5.5% | |
| Q2 2023 | -4.7% | -8.8% | +4.2% | |
| Q1 2023 | -4.1% | -2.3% | -8.7% | |
| Q4 2022 | -3.4% | +0.8% | +23.3% | |
| Q3 2022 | +2.0% | -3.9% | +14.4% | |
| Q2 2022 | +25.1% | +18.1% | +4.6% | |
| Q1 2022 | -8.2% | +3.7% | +33.0% | |
| Q4 2021 | +8.1% | +15.5% | -1.1% | |
| Q2 2021 | -5.8% | -8.1% | +5.4% | |
| Q4 2020 | -1.2% | +4.5% | -5.9% | |
| Q4 2019 | -1.2% | +4.5% | -5.9% | |
| Q3 2020 | -0.2% | +1.4% | +61.6% | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro